Aaron B. Waxman

3 weeks ago | healio.com | Scott Buzby |Richard Smith |Aaron B. Waxman

Trial supports sotatercept as standard of care for high-risk patients with PAH• Sotatercept reduced risk for adverse outcomes in patients with advanced pulmonary arterial hypertension. • The trial was halted early due to positive efficacy data. CHICAGO — Sotatercept, an activin signaling inhibitor, was associated with improved outcomes in patients with advanced pulmonary arterial hypertension at high risk for death, a speaker reported.